

Pallasch CP, Schulz A, Kutsch N, et al. Overexpression of TOSO in CLL is triggered by B-cell receptor signaling and associated with progressive disease. *Blood*. 2008;112(10):4213-4219.

In Figure 4 on page 4218 in the 15 November 2008 issue, panel D is missing. The corrected figure is shown below.




Figure 4. Regulation of TOSO and apoptosis resistance. (A) TOSO mRNA expression after 24-hour incubation with B-cell receptor (BCR) stimulation, recombinant CD40L-expressing feeder cell lines, and combined BCR/CD40L stimulus; significant increase of TOSO by BCR stimulus ($P = .013$) and suppression by CD40L ($P = .007$). (B) Time-dependent course of TOSO expression at time points of 3, 24, 48, and 72 hours. (C) Percentage of apoptosis in CLL cells assessed by annexin V/7-AAD flow cytometry. Significantly decreased apoptosis rate by BCR stimulation ($P = .003$); CD40L nonsignificantly reduces apoptosis. Slightly elevated apoptosis in CD40L-treated CLL cells by addition of the FAS-agonistic antibody CH11. (D) TOSO protein expression after 72-hour incubation with B-cell receptor stimulus (BCR), recombinant CD40L-expressing feeder cell lines, and combined BCR/CD40L stimulus; increase of TOSO by BCR stimulus and suppression by CD40L. Densitometry quotient of TOSO/ β -actin is indicated accordingly. Box plots in panels A and C show median, 1st and 3rd quartiles, and whiskers (error bars) defined by, at most, 1.5 \times IQR.

DOI 10.1182/blood-2018-04-843490

© 2018 by The American Society of Hematology

Kruse-Jarres R, Johnsen JM. How I treat type 2B von Willebrand disease. *Blood*. 2018;131(12):1292-1300.

In Table 1 on page 1293 of the 22 March 2018 issue, the entries for 2 laboratory tests for type 2B von Willebrand disease are reversed. The entry for the von Willebrand factor antigen (VWF:Ag) test for should read, "Decreased to normal," and the entry for the VWF ristocetin cofactor activity (VWF:RCo) test should read, "Usually low." The errors have been corrected in the online version, which now differs from the print version.

DOI 10.1182/blood-2018-04-844357

© 2018 by The American Society of Hematology